Drugs / PEBEZERTINIB
PEBEZERTINIB
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05241873 | Mar 2022 → Jul 2024 | adenocarcinoma, bronchogenic carcinoma, metastatic malignant neoplasm in the brain, non-small cell lung carcinoma | Blueprint Medicines Corporation | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PEBEZERTINIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068412 ↗ |
| Known as | BLU-203139; | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068412 ↗ |
| Known as | BLU-451 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05241873 ↗ |
| Modality | Small molecule | — CHEMBL6068412 ↗ |
| Route | Oral | “administered orally by tablet QD or BID” NCT05241873 ↗ |